Alexander C. Egilman, BA; Audrey D. Zhang, AB; Joshua D. Wallach, PhD, MS; Joseph S. Ross, MD, MHS
Financial Support: This project was conducted as part of the Collaboration for Research Integrity and Transparency at Yale Law School, funded by the Laura and John Arnold Foundation, which supports Mr. Egilman, Ms. Zhang, and Drs. Wallach and Ross. The Laura and John Arnold Foundation played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The authors assume full responsibility for the accuracy and completeness of the ideas presented, which do not represent the views of any supporting institutions.
Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M19-1085.
Reproducible Research Statement: Study protocol and statistical code: Not available. Data set: Available from Dr. Ross (e-mail, email@example.com).
Table 1. Medicare Part D Spending on Single-Enantiomer Drugs and Estimated Potential Reduction in Spending by Substituting Their Racemic Precursors, 2011–2017
Table 2. Medicare Part D Beneficiary Spending on Single-Enantiomer Drugs and Estimated Potential Reduction in Spending by Substituting Their Racemic Precursors, 2011–2015
Egilman AC, Zhang AD, Wallach JD, et al. Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors. Ann Intern Med. 2019;171:521–523. [Epub ahead of print 13 August 2019]. doi: https://doi.org/10.7326/M19-1085
Download citation file:
Published: Ann Intern Med. 2019;171(7):521-523.
Published at www.annals.org on 13 August 2019
Healthcare Delivery and Policy.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use